Two new diagnostic tests for endometriosis have been approved for use on the National Health Service (NHS) in England, aiming to reduce the lengthy delays many women face before receiving a diagnosis. The National Institute for Health and Care Excellence (NICE) has authorized these non-invasive tests for primary care settings, marking a potential shift in how endometriosis is identified and managed.

Endometriosis is a chronic condition where tissue similar to the lining of the womb grows outside the uterus, causing pain and other symptoms that can severely impact daily life. Currently, diagnosis often requires laparoscopy, a surgical procedure under general anesthesia involving a small camera inserted into the abdomen, which can lead to long waiting times and delayed treatment. The average time to diagnosis in the UK is over nine years, with delays extending to more than 11 years for patients from ethnically diverse backgrounds, according to NICE data.

The two new tests seek to address these challenges by providing earlier and less invasive options. One, known as "Endotest," involves collecting a saliva sample to detect microRNAs—small biological molecules that serve as markers for endometriosis. The other, called "EndoSure," measures electrical signals in the gut through sensor pads placed on the abdomen. For EndoSure, patients fast for six to eight hours before drinking water until full during a 45-minute monitoring period.

Experts have welcomed these developments as a "game-changer." Dr. Gail Busby, a consultant gynecologist at Manchester University NHS Foundation Trust, highlighted how the tests could transform patient care by enabling diagnosis without invasive procedures, allowing treatment to begin sooner. She noted that earlier diagnosis would not only benefit individual patients but also reduce demand on surgical resources.

Similarly, Dr. Anastasia Chalkidou, director of NICE’s health technology program, emphasized that these tools offer clinicians improved methods to detect endometriosis earlier, potentially easing the burden of chronic pelvic pain that affects many women’s work and personal lives.

Advocacy groups also stressed the importance of reducing diagnostic delays, especially for women from ethnic minorities. Emma Cox, CEO of Endometriosis UK, pointed out that diagnosis times have worsened over the past decade and called the new tests a vital step toward better disease management and quality of life.

These tests are recommended for women with suspected endometriosis when clinical exams and imaging results, such as transvaginal ultrasounds, are normal or inconclusive. While laparoscopy remains the definitive diagnostic method, the availability of Endotest and EndoSure in primary care could expedite identification, improve treatment pathways, and potentially lessen the condition’s long-term impact on patients.